导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.90% | 1724/4773 |
| 近一周 | -1.53% | 2278/5465 |
| 近一月 | -2.35% | 1613/5421 |
| 近一季 | -4.34% | 1792/5231 |
| 近半年 | 0.69% | 1271/4920 |
| 近一年 | 5.36% | 1728/4394 |
| 近两年 | 43.52% | 1746/2954 |
| 近三年 | 29.12% | 1116/2253 |
| 成立以来 | 42.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.16% 2700/4961 |
12.38% 2186/5312 |
- - |
- - |
| 2025 | 16.02% 2494/4813 |
-0.44% 2252/3635 |
1.32% 2379/4076 |
14.81% 2870/4524 |
0.18% 2153/4813 |
| 2024 | 15.55% 913/3463 |
4.30% 461/2808 |
-1.12% 942/3014 |
15.07% 1826/3129 |
-2.63% 2147/3463 |
| 2023 | -8.36% 1004/2656 |
4.99% 846/2280 |
-4.22% 1098/2385 |
-3.15% 857/2515 |
-5.90% 1549/2655 |
| 2022 | -19.40% 845/2207 |
-13.12% 701/1919 |
5.50% 889/2016 |
-13.13% 839/2113 |
1.23% 1335/2208 |
| 2021 | 0.99% 696/1822 |
-2.20% 595/1255 |
6.56% 736/1330 |
-3.83% 661/1466 |
0.76% 1064/1822 |
| 2020 | - - |
- - |
- - |
17.68% 100/1164 |
9.40% 642/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信沪深300指数增强(LOF)C VS. 长安沪深300非周期A(740101) |